title: Increased serum midkine levels during hemodialysis using heparin in chronic renal failure.
abstract: The heparin-binding growth factor midkine (MK) has been implicated in neuron growth, angiogenesis, and inflammation. In this study, to elucidate the involvement of MK in the development of pathologies associated with uremia, we examined the serum MK levels in patients receiving hemodialysis (HD) by a highly sensitive enzyme-linked immunoassay. Although no significant difference was found between control serum and serum before dialysis in HD patients, serum MK levels increased significantly at the early stage of HD sessions using heparin and gradually decreased after dialysis. In normal controls, intravenous administration of heparin induced a similar sudden increase of MK, but the subsequent decrease was also rapid. In an in vitro study, MK was released in time- and heparin-dose dependent manner from cultured vessels, but not from peripheral leukocytes. These results indicate that, in HD patients, MK is released mainly from endothelial cells immediately after administration of heparin during HD and disappears gradually from blood due to renal impairment. This phenomenon might affect some complications associated with HD.
authors.affiliation: Department of Internal Medicine, Daiko Medical Center, 1-1-20 Daiko-minami, Higashi-ku, Nagoya 461-0047, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Fujisawa
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: H
authors.initials: H
authors.lastname: Muramatsu
authors.forename: T
authors.initials: T
authors.lastname: Shinzato
authors.forename: K
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: K
authors.initials: K
authors.lastname: Horie
authors.forename: Z
authors.initials: Z
authors.lastname: Cai
authors.forename: H
authors.initials: H
authors.lastname: Oka
authors.forename: I
authors.initials: I
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Muramatsu
authors.forename: K
authors.initials: K
authors.lastname: Maeda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001550:Benzamidines; D002352:Carrier Proteins / Q000097:blood*; D016207:Cytokines; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D005260:Female; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007124:Immunoenzyme Techniques; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D007962:Leukocytes / Q000166:cytology / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D000078792:Midkine; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000209:etiology
chemical_list: D000925:Anticoagulants; D001550:Benzamidines; D002352:Carrier Proteins; D016207:Cytokines; D006146:Guanidines; D000078792:Midkine; D006493:Heparin; C032855:nafamostat